Research may unlock enzyme's role in disease

January 3, 2014
UT Arlington research may unlock enzyme's role in disease
This image shows the first and second coordination spheres of the CDO active site. Credit: UT Arlington

A UT Arlington chemist doing National Science Foundation-funded research on enzymes that regulate human biology has uncovered characteristics that could be used to identify predisposition to conditions such as heart disease, diabetic ulcers and some types of cancer.

Brad Pierce, an assistant professor of chemistry/biochemistry at The University of Texas at Arlington, recently led a team that examined an oxygen utilizing iron enzyme called cysteine dioxygenase or CDO, which is found in high levels within heart, liver, and brain tissues. Enzymes are proteins that act as catalysts to enable metabolic functions, but under some circumstances these oxygen-dependent enzymes can also produce highly toxic side products called or ROS.

For the first time, Pierce's team found that mutations outside the CDO active site environment or "outer coordination sphere" have a profound influence on the release of ROS. Excess ROS has been linked to numerous age-onset human disease states.

"Most research in the past has focused on the active site inner coordination sphere of these enzymes, where the metal molecule is located," said Pierce. "What we're finding is that it's really the second sphere that regulates the efficiency of the enzyme. In essence, these interactions hold everything together during catalysis. When this process breaks down, the enzyme ends up spitting out high levels of ROS and increasing the likelihood of disease."

The study was published in December by the American Chemical Society journal Biochemistry. Pierce is corresponding author on the paper, with UT Arlington students Wei Li, Michael D. Pecore and Joshua K. Crowell as co-authors. Co-author Elizabeth J. Blaesi is a graduate research assistant at the University of Wisconsin.

Pierce believes the findings from the CDO enzyme could be applied to other oxygen-dependent enzymes, which make up about 20 percent of the enzymes in the human body.

"In principle, these findings could be extended to better understand how other enzymes within the class generate ROS and potentially be used to screen for genetic dispositions for ROS-related diseases," he said.

Pierce's research brings a new level of detail to study through the use of electron paramagnetic resonance or EPR, a technology similar to the magnetic resonance imaging or MRI used in the medical field. In fall 2012, the National Science Foundation awarded Pierce a three-year, $300,000 grant to study enzymes that are catalysts for the oxidation of sulfur-bearing molecules in the body.

"Dr. Pierce's research is a good example of how basic science can set a path toward discoveries that affect human health. We look forward to his continued exploration of these findings," said Pamela Jansma, dean of the UT Arlington College of Science.

Explore further: New anti-inflammatory drugs pinch off reactive oxygen species at the source

More information: Biochemistry. 2013 Dec 23;52(51):9104-19. DOI: 10.1021/bi4010232.

Related Stories

A designer enzyme for alternative energy

June 21, 2013

( —Imagine pulling energy out of thin air. Yi Lu and his colleagues are on that path, in a quest to find alternatives to fossil fuels. The team has designed an enzyme that can harvest the energy of atmospheric ...

New small-molecule catalyst does the work of many enzymes

October 3, 2013

Researchers report that they have created a man-made catalyst that is an "enzyme mimic." Unlike most enzymes, which act on a single target, the new catalyst can alter the chemical profiles of numerous types of small molecules. ...

Recommended for you

A new form of real gold, almost as light as air

November 25, 2015

Researchers at ETH Zurich have created a new type of foam made of real gold. It is the lightest form ever produced of the precious metal: a thousand times lighter than its conventional form and yet it is nearly impossible ...

Moonlighting molecules: Finding new uses for old enzymes

November 27, 2015

A collaboration between the University of Cambridge and MedImmune, the global biologics research and development arm of AstraZeneca, has led researchers to identify a potentially significant new application for a well-known ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.